TY - JOUR
T1 - Arginine-based cationic liposomes accelerate T cell activation and differentiation in vitro
AU - Li, Tianshu
AU - Tolksdorf, Felix
AU - Sung, Wenhan
AU - Sato, Hiroto
AU - Eppler, Felix J.
AU - Hotta, Morihiro
AU - Kolanus, Waldemar
AU - Takeoka, Shinji
N1 - Funding Information:
This work was partially supported by JSPS KAKENHI Grant Number JP19K20700 and Waseda University Grant for Special Research Projects (2017B-229, 2018B-214).
Funding Information:
The authors would like to thank Dr. Xiaobing Li, InvivoGen Ltd. for kindly providing Jurkat-Lucia TM NFAT cells, and the EUIJ Waseda program ‘Research Competition for Science and Engineering’ and the Japan Society for the Promotion of Science (JSPS) Core-to-Core program, A. Advanced Research Networks for promoting international collaboration.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/7/25
Y1 - 2022/7/25
N2 - Cationic liposomes are versatile lipid nanocarriers to improve the pharmacological properties of drug payloads. Recent advantages include the application of their intrinsic immunostimulatory effects to enhance immune activation. Herein, we report for the first time the structural effect of cationic lipids in promoting T cell activation and differentiation in vitro. Two types of cationic liposomes R3C14 and R5C14 were prepared from single type of lipids Arg-C3-Clu2C14 or Arg-C5-Clu2C14, which bear arginine head group and ditetradecyl tails but vary in the carbon number of the spacer in between. Murine CD8 or CD4 T cells were pretreated with 50 μM of each type of liposomes for 2 h, followed by stimulation with anti-CD3/CD28 antibodies for 24 h. In comparison to liposome-untreated T cells, R5C14-pretreatment induced a robust T cell activation (IL-2, CD25+) and differentiation into effector cells (CD44high, CD62Llow), whereas R3C14 did not show comparable effect. Furthermore, a weak activation of nuclear factor of activated T cells (NFAT) was detected in Jurkat-Lucia NFAT cells (InvivoGen), suggesting a potential signaling pathway for the liposomal effect. Although R5C14 liposomes did not activate T cells without subsequent CD3/CD28 stimulation, this study implied a recessive effect of some cationic adjuvant in priming T cells to enhance their responsiveness to antigens.
AB - Cationic liposomes are versatile lipid nanocarriers to improve the pharmacological properties of drug payloads. Recent advantages include the application of their intrinsic immunostimulatory effects to enhance immune activation. Herein, we report for the first time the structural effect of cationic lipids in promoting T cell activation and differentiation in vitro. Two types of cationic liposomes R3C14 and R5C14 were prepared from single type of lipids Arg-C3-Clu2C14 or Arg-C5-Clu2C14, which bear arginine head group and ditetradecyl tails but vary in the carbon number of the spacer in between. Murine CD8 or CD4 T cells were pretreated with 50 μM of each type of liposomes for 2 h, followed by stimulation with anti-CD3/CD28 antibodies for 24 h. In comparison to liposome-untreated T cells, R5C14-pretreatment induced a robust T cell activation (IL-2, CD25+) and differentiation into effector cells (CD44high, CD62Llow), whereas R3C14 did not show comparable effect. Furthermore, a weak activation of nuclear factor of activated T cells (NFAT) was detected in Jurkat-Lucia NFAT cells (InvivoGen), suggesting a potential signaling pathway for the liposomal effect. Although R5C14 liposomes did not activate T cells without subsequent CD3/CD28 stimulation, this study implied a recessive effect of some cationic adjuvant in priming T cells to enhance their responsiveness to antigens.
KW - Arginine-based cationic liposomes
KW - CD3/CD28 stimulation
KW - Lipid nanocarriers
KW - Nuclear factor of activated T cells (NFAT)
KW - T cell activation and differentiation
UR - http://www.scopus.com/inward/record.url?scp=85132707761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132707761&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2022.121917
DO - 10.1016/j.ijpharm.2022.121917
M3 - Article
C2 - 35714814
AN - SCOPUS:85132707761
SN - 0378-5173
VL - 623
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 121917
ER -